CRDF

Cardiff Oncology, Inc.

TrovaGene Inc is clinical-stage, precision medicine oncology therapeutics company. Its focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its Precision Cancer Monitoring technology.

Cardiff Oncology, Inc. (CRDF) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C
Factor Score 2.2 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
A+
Factor Score 5.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.5
EV / EBITDA -0.7
Rev Growth YoY -14.1%
Gross Margin 0.0%
Price Return 3M -20.2%
Price Return 12M -63.9%
Catalyst Signal 0.00
Market Cap $61.8M
TTM Revenue $508.0K
Price / Sales 121.7
ROE -94.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C (2.2) C- (1.9) D (1.5) C- (2.0) A+ (5.0) C+ (2.5)
2026-11-04 C- (2.1) D+ (1.8) D (1.4) C (2.2) C+ (2.7) C- (2.0)
2026-10-28 C (2.2) D+ (1.8) D (1.5) C (2.4) C+ (2.7) C- (2.1)
2026-10-21 C (2.2) D+ (1.8) D (1.4) C+ (2.5) C+ (2.6) C- (2.1)
2026-10-14 C- (2.1) D+ (1.8) D (1.4) C+ (2.6) C+ (2.6) C- (2.1)
Page 1 of 8
…